Released Mar 14, 2019, after the close
10-K filed Mar 14, 2019, 73 days after period end · 0001564590-19-007805
Q4 2018 · 10-K
Revenue$1.69M$1.69M +70.4% vs Q4 2017+157.1% vs Q3 2018
Net Income-$10.60M-$10.60M N/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$0.60-$0.60 N/M vs Q4 2017N/M vs Q3 2018
Operating Incomederived-$11,084,000N/M
Operating Cash Flowderived-$13,509,000N/M
Free Cash Flowderived-$15,923,000—
Margins · derived
Operating margin-655.1%+754.8 pt vs Q4 2017
Net margin-626.4%+769.6 pt vs Q4 2017
What the release said
The release
Same quarter
| Metric | Q4 2018 | Q4 2017 | Q4 2016 |
|---|---|---|---|
| Revenue | $1.69M | $993.00K | — |
| Net Income | -$10.60M | -$13.86M | -$7.21M |
| EPS Diluted | -$0.60 | -$1.59 | -$25.68 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR